Re­gen­eron, Sanofi slash Pralu­ent list price mir­ror­ing Repatha dis­count

Fol­low­ing Am­gen’s de­ci­sion to slash the price of its cho­les­terol drug Repatha by 60% to $5,850 last year, the team be­hind their main ri­val treat­ment, Pralu­ent — Re­gen­eron $REGN and Sanofi $SNY — have fol­lowed suit with the same dis­count, be­gin­ning ear­ly March.

Fol­low­ing ap­provals in 2015 the two drugs were pegged to at­tain block­buster sta­tus for their abil­i­ty to dra­mat­i­cal­ly low­er lev­els of LDL cho­les­terol, but in­stead faced push­back from in­sur­ers for their high stick­er prices that led to low­er adop­tion than ex­pect­ed, de­spite lat­er tri­als that demon­strat­ed the PC­SK9 in­hibitors al­so sig­nif­i­cant­ly cut the risk of heart at­tacks and stroke. Un­like Repatha, Pralu­ent has al­so shown to low­er the risk of death.  

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN